Loading…
Employees: 1,990
Size Guangdong Hybribio Biotech (300639.SZ) is a China Health Care company (Medical Specialties) with a market value of $568M, the 3556th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.74 on 6 Nov 2026.
Performance Over six months the shares fell 5.3%, against -13.2% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue fell 7.2% over the last twelve months (peer median +9.3%); the operating margin is 4.4% (peer median 6.3%).
Valuation It trades at 63.8× forward earnings against a peer median of 24.8× (2nd most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.3 points below its cost of capital (5.6% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥642M | CN¥665M | CN¥812M | CN¥1.10B | CN¥5.58B |
| Revenue growth | — | -18% | -26% | -80% | — |
| Gross profit | CN¥353M | CN¥215M | CN¥296M | CN¥579M | CN¥3.76B |
| EBITDA | n/a | -CN¥16.2M | -CN¥615M | CN¥189M | CN¥2.61B |
| Net income | CN¥66.7M | -CN¥131M | -CN¥655M | CN¥140M | CN¥1.73B |
| Free cash flow | CN¥231M | CN¥251M | -CN¥69.6M | -CN¥58.1M | CN¥575M |
| Capital expenditure | CN¥147M | CN¥92.4M | CN¥148M | CN¥385M | CN¥734M |
| Total debt | CN¥178M | CN¥89.6M | CN¥87.5M | CN¥56.7M | CN¥139M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300639.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -0.3% | 7th lowest of 20 |
| 6-month return | -5.3% | -13.2% | 9th highest of 20 |
| Distance from 52-week high | -43.0% | -37.3% | 8th lowest of 20 |
| Revenue growth (TTM) | -7.2% | +9.3% | 4th lowest of 20 |
| Operating margin | 4.4% | 6.3% | 10th lowest of 20 |
| Forward P/E | 63.8× | 24.8× | 2nd most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 2.7% | 7.8% | 2nd least demanding of 10 |
| Growth delivered (Del g) | -13.2% | +6.5% | 2nd lowest of 10 |
| Hurdle (Req g minus delivered) | +15.9 pp | +5.1 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | -1.3 pp | -1.6 pp | 9th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 25.2× | 6.3% | +24.4% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 90.3× | 34.4% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 28.2× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 24.4× | 5.0% | +5.0% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | n/a | n/a | n/a |